Optimization of virotherapy for cancer

Matt Biesecker, Jung H. Kimn, Huitian Lu, David M Dingli, Željko Bajzer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Several viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus, it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor. The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been developed that provided considerable insights on the potential therapeutic scenarios. However, virotherapy is potentially risky since large amounts of a replicating virus are injected in the host with a risk of adverse effects. Therefore, the optimal dose, number of doses, and timing are expected to play an important role on the outcome both for the tumor and the host. In the current work, we combine a model of the dynamics of tumor virotherapy that was validated with experimental data with optimization theory to illustrate how we can improve the outcome of tumor therapy. In this first report, we demonstrate that (i) in most circumstances, anything more than two administrations of a vector is not helpful, (ii) correctly timed delivery of the virus provides superior results compared to regularly scheduled therapy or continuous infusion, (iii) a second dose of virus that is not properly timed leads to a worse outcome compared to a single dose of virus, and (iv) it is less costly to treat larger tumors.

Original languageEnglish (US)
Pages (from-to)469-489
Number of pages21
JournalBulletin of Mathematical Biology
Volume72
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

tumor
Viruses
Tumors
Tumor
cancer
Cancer
Virus
virus
viruses
neoplasms
Optimization
Neoplasms
Dose
therapeutics
Therapy
dosage
Cell Population
Cells
Population dynamics
Optimization Theory

Keywords

  • Modeling virotherapy
  • Optimization methods

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Computational Theory and Mathematics
  • Environmental Science(all)
  • Immunology
  • Mathematics(all)
  • Neuroscience(all)
  • Pharmacology

Cite this

Optimization of virotherapy for cancer. / Biesecker, Matt; Kimn, Jung H.; Lu, Huitian; Dingli, David M; Bajzer, Željko.

In: Bulletin of Mathematical Biology, Vol. 72, No. 2, 02.2010, p. 469-489.

Research output: Contribution to journalArticle

Biesecker, M, Kimn, JH, Lu, H, Dingli, DM & Bajzer, Ž 2010, 'Optimization of virotherapy for cancer', Bulletin of Mathematical Biology, vol. 72, no. 2, pp. 469-489. https://doi.org/10.1007/s11538-009-9456-0
Biesecker, Matt ; Kimn, Jung H. ; Lu, Huitian ; Dingli, David M ; Bajzer, Željko. / Optimization of virotherapy for cancer. In: Bulletin of Mathematical Biology. 2010 ; Vol. 72, No. 2. pp. 469-489.
@article{770039a2ff4a42f898ab78bc6420e116,
title = "Optimization of virotherapy for cancer",
abstract = "Several viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus, it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor. The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been developed that provided considerable insights on the potential therapeutic scenarios. However, virotherapy is potentially risky since large amounts of a replicating virus are injected in the host with a risk of adverse effects. Therefore, the optimal dose, number of doses, and timing are expected to play an important role on the outcome both for the tumor and the host. In the current work, we combine a model of the dynamics of tumor virotherapy that was validated with experimental data with optimization theory to illustrate how we can improve the outcome of tumor therapy. In this first report, we demonstrate that (i) in most circumstances, anything more than two administrations of a vector is not helpful, (ii) correctly timed delivery of the virus provides superior results compared to regularly scheduled therapy or continuous infusion, (iii) a second dose of virus that is not properly timed leads to a worse outcome compared to a single dose of virus, and (iv) it is less costly to treat larger tumors.",
keywords = "Modeling virotherapy, Optimization methods",
author = "Matt Biesecker and Kimn, {Jung H.} and Huitian Lu and Dingli, {David M} and Željko Bajzer",
year = "2010",
month = "2",
doi = "10.1007/s11538-009-9456-0",
language = "English (US)",
volume = "72",
pages = "469--489",
journal = "Bulletin of Mathematical Biology",
issn = "0092-8240",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Optimization of virotherapy for cancer

AU - Biesecker, Matt

AU - Kimn, Jung H.

AU - Lu, Huitian

AU - Dingli, David M

AU - Bajzer, Željko

PY - 2010/2

Y1 - 2010/2

N2 - Several viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus, it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor. The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been developed that provided considerable insights on the potential therapeutic scenarios. However, virotherapy is potentially risky since large amounts of a replicating virus are injected in the host with a risk of adverse effects. Therefore, the optimal dose, number of doses, and timing are expected to play an important role on the outcome both for the tumor and the host. In the current work, we combine a model of the dynamics of tumor virotherapy that was validated with experimental data with optimization theory to illustrate how we can improve the outcome of tumor therapy. In this first report, we demonstrate that (i) in most circumstances, anything more than two administrations of a vector is not helpful, (ii) correctly timed delivery of the virus provides superior results compared to regularly scheduled therapy or continuous infusion, (iii) a second dose of virus that is not properly timed leads to a worse outcome compared to a single dose of virus, and (iv) it is less costly to treat larger tumors.

AB - Several viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus, it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor. The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been developed that provided considerable insights on the potential therapeutic scenarios. However, virotherapy is potentially risky since large amounts of a replicating virus are injected in the host with a risk of adverse effects. Therefore, the optimal dose, number of doses, and timing are expected to play an important role on the outcome both for the tumor and the host. In the current work, we combine a model of the dynamics of tumor virotherapy that was validated with experimental data with optimization theory to illustrate how we can improve the outcome of tumor therapy. In this first report, we demonstrate that (i) in most circumstances, anything more than two administrations of a vector is not helpful, (ii) correctly timed delivery of the virus provides superior results compared to regularly scheduled therapy or continuous infusion, (iii) a second dose of virus that is not properly timed leads to a worse outcome compared to a single dose of virus, and (iv) it is less costly to treat larger tumors.

KW - Modeling virotherapy

KW - Optimization methods

UR - http://www.scopus.com/inward/record.url?scp=77951239900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951239900&partnerID=8YFLogxK

U2 - 10.1007/s11538-009-9456-0

DO - 10.1007/s11538-009-9456-0

M3 - Article

C2 - 19787406

AN - SCOPUS:77951239900

VL - 72

SP - 469

EP - 489

JO - Bulletin of Mathematical Biology

JF - Bulletin of Mathematical Biology

SN - 0092-8240

IS - 2

ER -